Phase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia
Frew, Paula M
Thomas, Shontell N
Easley, Kirk A
Chow, H-H Sherry
Ura, Chiemi A
AffiliationUniv Arizona, Dept Med
MetadataShow full item record
PublisherDOVE MEDICAL PRESS LTD
CitationPhase I dose-escalation trial of intravaginal curcumin in women for cervical dysplasia 2016, Volume 9:1 Open Access Journal of Clinical Trials
Rights© 2017 Gattoc et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractBackground: This is a Phase I trial demonstrating safety and tolerability of intravaginal curcumin for future use in women with cervical neoplasia. Objective: The objective of this study was to assess the safety, tolerability, and pharmacokinetics of intravaginal curcumin in healthy women. Study design: We conducted a 3+3 dose-escalation Phase I trial in a group of women aged 18-45 years. Thirteen subjects were given one of four doses of curcumin powder (500 mg, 1,000 mg, 1,500 mg, and 2,000 mg) packed in gelatin capsules, which was administered intra-vaginally daily for 14 days. The primary end point for this study was safety based on severe adverse events regarding laboratory toxicity, clinical findings, and colposcopic abnormalities. We administered an acceptability questionnaire to assess product experience and attributes. Results: No dose-limiting toxicities (0/13) were experienced (95% confidence interval: 0.0%-22.8%) in this study. The pharmacokinetics data demonstrated that curcumin and curcumin conjugates were not measurable in the serum and negligible in the urine of the study participants. Although 23 adverse events occurred during the course of the trial, all events were grade I based on the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and were resolved by the end of the study in an average of 9 days. Fifty-six percent of the adverse events were related to the study drug, which included genital pruritus (23% of subjects), vaginal discharge (100%), vaginal dryness (15%), abnormal prothrombin (23%), and hypokalemia (8%). Conclusion: Intravaginal curcumin was well tolerated by all subjects and safe. In this Phase I trial, there were no severe adverse events observed at any of the administered dose levels. All adverse events were grade I and did not result in early termination of the study. There was no evidence of systemic absorption or significant local absorption of intravaginally administered curcumin.
NoteOpen access journal
VersionFinal published version
SponsorsPHS Grant from Clinical and Translational Science Award program [UL1 RR025008]; National Institutes of Health; National Center for Research Sources; Emory Medical Care Foundation ; Center for AIDS Research at Emory University [P30 AI050409]; Emory URC Grant; Coca-Cola Enterprises Research Award by Winship Cancer Institute of Emory University